恩沃利单抗联合阿帕替尼二线治疗复发/转移程序性死亡受体配体1阳性晚期宫颈癌患者的效果
Effect of envafolimab combined with apatinib in second-line treatment of recurrent/metastatic programmed cell death 1 ligand 1 positive advanced cervical cancer patients
万晶晶 1韩永清2
作者信息
- 1. 江西医学高等专科学校临床医学院,江西 上饶 334000
- 2. 上饶市人民医院肿瘤科,江西 上饶 334000
- 折叠
摘要
目的 探讨恩沃利单抗联合阿帕替尼二线治疗复发/转移程序性死亡受体配体1(PD-L1)阳性晚期宫颈癌患者的效果.方法 根据治疗方法的不同将70例复发/转移PD-L1阳性晚期宫颈癌患者分为观察组(n=39,恩沃利单抗联合阿帕替尼二线治疗)和对照组(n=31,阿帕替尼二线治疗),比较两组患者的肿瘤标志物[血管内皮生长因子(VEGF)、鳞状细胞癌抗原(SCCA)]水平、免疫功能指标(CD3+、CD4+、CD8+、CD4+/CD8+)、临床疗效及不良反应发生情况.结果 治疗后,两组患者VEGF、SCCA、CD8+水平均低于本组治疗前,CD3+、CD4+水平及CD4+/CD8+均高于本组治疗前,观察组患者VEGF、SCCA、CD8+水平均低于对照组,CD3+、CD4+水平及CD4+/CD8+均高于对照组,差异均有统计学意义(P﹤0.05).观察组患者的总有效率高于对照组,差异有统计学意义(P﹤0.05).两组患者的不良反应总发生率比较,差异无统计学意义(P﹥0.05).结论 恩沃利单抗联合阿帕替尼二线治疗复发/转移PD-L1阳性晚期宫颈癌患者,能够降低肿瘤标志物水平,提高患者的免疫功能,具有较好的临床疗效,且安全性高.
Abstract
Objective To investigate the effect of envafolimab combined with apatinib in second-line treatment of re-current/metastatic programmed cell death 1 ligand 1(PD-L1)positive advanced cervical cancer patients.Method A total of 70 patients with recurrent/metastatic PD-L1 positive advanced cervical cancer were divided into observation group(n=39,envafolimab combined with apatinib second-line treatment)and control group(n=31,apatinib second-line treatment)according to different treatment methods.The tumor markers[vascular endothelial growth factor(VEGF),squamous cell carcinoma antigen(SCCA)]levels,immune function indexes(CD3+,CD4+,CD8+,CD4+/CD8+),clinical efficacy and inci-dence of adverse reactions were compared between the two groups.Result After treatment,the VEGF,SCCA and CD8+levels in two groups were lower than those before treatment,the CD3+,CD4+levels and CD4+/CD8+were higher than those before treatment,the VEGF,SCCA and CD8+levels in observation group were lower than those in control group,the CD3+,CD4+levels and CD4+/CD8+were higher than those in control group,and the differences were statistically sig-nificant(P<0.05).The total effective rate in observation group was higher than that in control group,and the difference was statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions be-tween the two groups(P>0.05).Conclusion Envafolimab combined with apatinib in the second-line treatment of pa-tients with recurrent/metastatic PD-L1 positive advanced cervical cancer can reduce the tumor marker levels and improve the immune function of patients,with good clinical efficacy and high safety.
关键词
恩沃利单抗/阿帕替尼/宫颈癌/程序性死亡受体配体1/二线治疗Key words
envafolimab/apatinib/cervical cancer/programmed cell death 1 ligand 1/second-line treatment引用本文复制引用
基金项目
江西省卫生健康委科技计划项目(202410960)
出版年
2024
NETL
NSTL
万方数据